Agenus Inc news

   Watch this stock
Showing stories 1 - 10 of about 89   

Articles published

AGEN 8.61 -0.17 (-1.94%)
price chart
3 Sizzling Hot Biotech Stocks - Agenus Inc (NASDAQ:AGEN), Alexion ...
Mr. Ballantyne brings more than 30 years of financial and operations experience to Agenus. Most recently, Mr. Ballantyne served as the Chief Financial Officer at Synthetic Biologics, Inc., a publicly-traded biotechnology company, from February 2012 to ...
Agenus Inc. (NASDAQ:AGEN) Brokerage Rating Update  Investor Newswire
Analyst Price Target Update on Agenus Inc.  OTC Outlook
Agenus Inc. (NASDAQ:AGEN) Analyst Rating Update
Agenus Inc. (NASDAQ:AGEN) stock has received a short term price target of $ 12.5 from 2 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $2.12.
Agenus (AGEN) - Research Analysts' Weekly Ratings Changes  Dakota Financial News
HC Wainright Begins Coverage on Agenus (AGEN)  The Legacy
Agenus Inc (NASDAQ:AGEN) on Watch List
[ZACKS] Agenus Inc (NASDAQ:AGEN)(TREND ANALYSIS) shares were up 4% on the extension of its existing collaboration and license agreement with Merck MRK for the discovery and development of therapeutic antibodies to Merck's proprietary immune ...
Momentum Stock in Focus: Agenus Inc. (NASDAQ:AGEN)  Enterprise Leader
Agenus Rating Lowered to Sell at Zacks (AGEN)  WKRB News
Agenus Inc (NASDAQ:AGEN) Initiated with a Buy at H.C. Wainwright
In analysts report issued today, H.C. Wainwright analysts began Agenus Inc (NASDAQ:AGEN) coverage with Buy rating. In spite of the new coverage NASDAQ:AGEN is currently trading -0.37% lower at $8.06 as of 05:35 New York time.
Oppenheimer Rating Update on Agenus Inc. (NASDAQ:AGEN)  News Watch International
Company Shares of Agenus Inc. Drops by -6.26%  Insider Trading Report
Biotech Stocks that your portfolio will love - Agenus Inc (NASDAQ:AGEN ...
Mr. Ballantyne brings more than 30 years of financial and operations experience to Agenus. Most recently, Mr. Ballantyne served as the Chief Financial Officer at Synthetic Biologics, Inc., a publicly-traded biotechnology company, from February 2012 to ...
Oppenheimer Initiates Coverage on Agenus Inc Following Collaborations With ...
Oppenheimer analyst Christopher Marai initiated coverage on Agenus Inc (NASDAQ:AGEN) after the company began collaborations with Merck and Incyte for the discovery and development of therapeutic antibodies for the treatment of cancer.
Agenus Inc. Analyst Rating Update  Insider Trading Report
Brokerage Firm Price Target on Agenus Inc. (NASDAQ:AGEN)  News Watch International
Agenus Inc. (NASDAQ:AGEN) Price Target Update
Agenus Inc. (NASDAQ:AGEN): According to 3 Analysts, The short term target price has been estimated at $ 11.67.The target price could deviate by a maximum of $2.08 from the forecast price.
Analyst Rating Update on Agenus Inc.  News Watch International
Agenus Downgraded by Zacks (AGEN)  The Legacy
Agenus Inc. (NASDAQ:AGEN) Analyst Rating in Focus
Agenus Inc. (NASDAQ:AGEN) shares have been given a 1 rating by analysts surveyed by Zacks Investment Research. Sell-side firms often use different terminology for their ratings so this scale provides a simple consensus number.
Oppenheimer Analyst Rating on Agenus Inc.
Agenus Inc. (NASDAQ:AGEN) witnessed a decline in the market cap on Friday as its shares dropped 0.23% or 0.02 points. After the session commenced at $8.61, the stock reached the higher end at $8.83 while it hit a low of $7.6201.
Can Agenus Inc. (NASDAQ:AGEN) Surprise Analysts this Quarter?  Investor Newswire
Zacks Short Term Rating on Agenus Inc. (NASDAQ:AGEN)  Insider Trading Report
Agenus, Inc. – Product Pipeline Review – 2015 | Researchmoz
This report provides comprehensive information on the current therapeutic developmental pipeline of Agenus, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of ...